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Inflammatory bowel disease (IBD) is a chronic and multifactorial disease of the gas-
trointestinal tract. The exact etiology of IBD remains complex and unclear involving
an inadequately defined relationship between microbial insult, genetic predisposition,
altered intestinal barrier permeability, oxidative stress components and abnormal immune
responses. The role of the co-stimulatory system made up of cluster of differentiation 40
protein (CD40) and its ligand (CD40L) in the response of the immune system to pathogens
is nowwidely accepted. The implication of CD40/CD40L axis in immune system disorders
due to its important role as signal transduction pathway among immune cells is well
documented. Several studies have suggested that CD40/CD40L interactions regulate
oxidative stress; this can affect various signaling pathways leading to IBD development.
Hence, CD40/CD40L signaling pathwaymay become a new target for IBD treatment. This
review will cover the general contribution of the CD40/CD40L dyad in the development
of IBD in order to facilitate future approaches aiming to elucidate the immunological
mechanisms that control gut inflammation.
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INFLAMMATORY BOWEL DISEASE
Inflammatory bowel diseases (IBDs) are chronic inflammatory disorder of the bowel. Their
complex, multifactorial etiology remains unclear. Currently, the common assumption to explain
the development of IBD would be a dysregulation of the mucosal immune response against
intestinal flora elements, occurring in genetically predisposed patients (1). Crohn’s disease (CD)
and ulcerative colitis (UC) are collectively referred to as IBD due to their common symptoms,
characterized by evolution in spurts, interspersed with periods of remission. These two forms have
an increasing severity and intensity over time and have important anatomical and pathological
distinctions in particular regarding the extent and depth of the damage. The pathogenesis of
these IBD entities results from a complex interaction of genetic, environmental, immunologic,
and oxidative stress components, primarily driven by defects of the mucosal barrier (2, 3).
They are characterized by recurring inflammation of the small and large intestine. Infiltration of
Abbreviations: APC, antigen-presenting cell; CD, Crohn’s disease; CD40, cluster of differentiation 40; CD40L, cluster of
differentiation 40 ligand; DCs, dendritic cells; HIGM, X-linked hyper-IgM syndrome; IBD, inflammatory bowel disease; Ig,
immunoglobulin; IFN-γ, gamma interferon; IL, interleukin; Th, T helper; TNFR, tumor necrosis factor receptor; TRAFs,
TNFR-associated factors; UC, ulcerative colitis.
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macrophages, T and B lymphocytes into the intestinal epithelium
disrupts its barrier function, resulting in diarrhea, abdominal
pain, rectal bleeding, and malnutrition in attained individuals
(4). Inflammatory lesions are secondary to an inappropriate and
exaggerated immune response up to the entire bowel wall as in
CD or confined to the surface layers as in UC. Inflammation in
CD is characterized by the predominant production of Th1/Th17
type cytokines, such as IFN-γ, IL-12, and IL-17 (5, 6). While
inflammation in UC is characterized by production of Th2-type
cytokines, such as IL-13, IL-4, and IL-5 (5, 7). In addition, this
incongruous activation of the immune system will lead to a per-
turbation of the immune balance that is necessary to maintain
intestinal homeostasis.
Given its central role as a key regulator and amplifier of
immune reactivity, the CD40/CD40 ligand (CD40L) system sig-
nificantly contributes to the development and progression of mul-
tiple autoimmune diseases, including IBD. The present review
discusses the latest observations relevant to the role of the
CD40/CD40L pathway in the development of IBD.
THE CD40/CD40L AXIS
Since its initial discovery more than two decades ago, the
CD40/CD40L dyad has gained much attention in the scientific
community. The pivotal role of CD40/CD40L dyad in immunity
was initially evidenced by the finding that patients suffering from
the X-linked hyper-IgM syndrome (HIGM) are characterized by
mutations in their CD40L gene, resulting in loss of function in the
CD40L protein. The resulting inactive CD40L protein is unable to
induce T cell-dependent B cell responses, which are characterized
by severe defects in humoral immunity as well as the absence of
IgG, IgA, and IgE antibodies due to a lack of B cell Ig isotype
switching (8). Now, it is clear that aside from its importance
for appropriate immune responses, the CD40/CD40L dyad has
a much broader cell expression pattern (Table S1 in Supplemen-
tary Material) and it is associated with diverse physiological and
pathological processes (Table S2 in Supplementary Material).
A noteworthy role of CD40/CD40L in oxidative stress was
first demonstrated in murine B lymphocytes, where increased
production of reactive oxygen intermediates upon CD40 liga-
tion correlated with c-Jun N-terminal kinase activation and IL-
6 secretion (9). Moreover, activation of CD40 receptor increases
oxidative stress by enhancing formation of endogenous ROS and
as consequence inhibits endothelial cell migration (10). This role
was further confirmed in mouse models where CD40 or CD40L
deficiency abrogated hypercholesterolemia-induced oxidative
stress (11).
CD40 is a member of the tumor necrosis factor recep-
tor (TNFR) superfamily, which is constitutively or inducibly
expressed on the surface of a variety of immune and non-immune
cell types including B cells, macrophages, dendritic cells (DCs),
microglia, endothelial cells, epithelial cells, and keratinocytes (12,
13). It was initially identified on B lymphocytes by antibody bind-
ing, then cloned in the Burkitt lymphoma Raji cell line, revealing
a cDNA encoding for a 1.5 kb mRNA (14, 15).
Its ligand, CD40L (also known as CD154, gp39, TBAM, and
TRAP), is a type II transmembrane protein belonging to the
TNF superfamily (16) and is transiently expressed on the surface
of activated CD4+ T cells, but can also be up-regulated on
other cell types in the context of autoimmune disease (17, 18).
The CD40–CD40L interaction results in movement of CD40
into cholesterol-rich membrane microdomains and the binding
of TNFR-associated factors (TRAFs) to its cytoplasmic tail (12,
19). Specific TRAF molecules are associated with overlapping
and distinct CD40-mediated functions (19). CD40 directly binds
TRAF2, TRAF3, TRAF5, and TRAF6, and indirectly associates
with TRAF1 (19). These interactions result in activation of mito-
gen and stress-activated protein kinase (MAPK/SAPK) cascades,
transcription factor activation, cytokine secretion, proliferation
and differentiation of B cells into Ig-secreting plasma cells, and
humoral memory establishment.
MECHANISM OF ACTION
Up to date, there are three proposed mechanisms for the con-
tribution of the CD40/CD40L dyad to T lymphocyte-dependent
autoimmune diseases. The first proposed mechanism is mediated
through improper T lymphocyte selection in the thymus. As
CD40 has been shown to cooperate with the receptor activator of
NF-κB (RANK) in promoting medullary thymic epithelial cells
development, a disruption in CD40 activation in these cells could
probably result in their inadequate development (20). Therefore,
the disturbed development of medullary thymic epithelial cells
potentially permits auto-reactive T lymphocyte clones to escape
negative selection, leading to failure of central tolerance and
the subsequent potential development of autoimmune diseases.
The second proposed mechanism of CD40/CD40L contribution
to autoimmune diseases occurs in secondary lymphoid organs,
where T lymphocytes are primed by APCs (B lymphocytes or
DCs) over-expressing CD40 either constitutively or transiently
(20). The overexpression of CD40 leads to increased interactions
between CD40L on T lymphocytes and CD40 on APCs, which
favor the activation of auto-reactive T lymphocytes as well as the
production of pro-inflammatory cytokines by antigen-presenting
cells and auto-antibodies by B lymphocytes (21). Among the
secreted pro-inflammatory cytokines, IL-6 has been shown to
drive T lymphocytes differentiation into Th17 cells (21). In turn,
Th17 cells induce cell-mediated tissue damage by secreting IL-17
(22). Therefore, the increase in CD40 expression and the sub-
sequent exaggerated CD40/CD40L interactions potentially lead
to the development of autoimmune diseases. The third pro-
posed mechanism results from abnormal expression of CD40
in tissues where it is normally undetectable. Under such condi-
tions, the tissues themselves contribute to the initiation of the
autoimmune disease. Indeed, elevated expression levels of CD40
in target tissues (thyroid and pancreatic islet cells) have been
associated with the initiation of thyroiditis and the production
of inflammatory cytokines resulting in the failure of pancreatic
islet cell transplants (23, 24). Otherwise, CD40/CD40L axis could
be involved in the generation of Treg cells. Thus, the precise
nature of the signals involving the generation of Treg cells has
not been yet clarified, all we know is that Treg formation in
the thymus is due to the involvement of TCR recognition of
MHC-II expressed on thymic epithelium (25–27). However, a
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study published by Guiducci et al. demonstrated that there is a
decrease in Treg number in the thymus of CD40 /  mice, and
of normal mice treated with Ab blocking CD40L, suggests that
CD40/CD40L interaction takes part in the generation of Treg
cells. Moreover, strong defects in survival and homeostatic pro-
liferation were observed in CD40 /  mice; however, the admin-
istration of exogenous IL-2 corrected these defects in CD40 / 
animals (28). Therefore, an overexpression of CD40/C40L could
imply an increased generation of Treg cells promoting IBD since
it is characterized by gut infiltration of highly reactive Treg
cells (29).
Finally, we illustrated in Figure 1 the different pathways trig-
gered by the axis CD40/CD40L in activated DCs.
CD40/CD40L PATHWAY IN
INFLAMMATORY BOWEL DISEASE
The CD40/CD40L pathway activation is involved in the patho-
genesis of IBD. Enhanced expression of CD40 and CD40L in
the gut mucosa in IBD is reported (30–32). Furthermore, higher
sCD40L levels in the circulation of IBD patients (33) as well as
CD patients with abscesses and/or fistulas (34) were also pointed
out, reflecting elevated surface expression and release of CD40L
by activated platelets and activation of functional CD40L in the
intestine.
The CD40/CD40L interaction was shown to be critical for
the development of IBD through activation of various pathways
FIGURE 1 | CD40/CD40L axis in activated dendritic cells. CD40/CD40L axis is implicated in many downstream pathways in activated dendritic cells that are
essential for its function. CD40L induces the activation of dendritic cells through its binding to CD40. This activation requires the recruitment of the TRAFs family. This
leads in turn to the activation of several pathways, such as STAT3, NF-κB, and MKKs. They are all mostly involved in many gene expressions that include cell
survival, cell adhesion as well as procoagulant activity and pro-inflammatory cytokines production. On the other side, other pathways that go through different
receptors influence DC activity, among them TNF-α inducing mostly an pro-atherogenic activity or IL-10 receptor that can enhance an opposite function and
therefore promote an anti-atherogenic activity in DC.
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related to inflammation in immune and non-immune cells. The
initial evidences pointing the contribution of CD40/CD40L to the
autoimmune IBD came from studies in mice. The results from
these studies demonstrated that the CD40/CD40L interactions
were an important element in the pathogenesis of colitis. In fact,
administration of a blocking CD40L antibody at the onset of
colitis initiation inhibits lymphocytic infiltration into the intesti-
nal epithelium, and disease occurrence, whereas blocking CD40L
4weeks following colitis initiation only improves the disease
symptoms (35, 36).
Additionally, T lymphocytes CD40L overexpression in mice,
results in T lymphocyte infiltration in multiple organs and death
caused by IBD by 3–6weeks of age (37). The particular relevance
of this system in CD or UC is further emphasized by evidence
obtained from IBD patients. CD40, CD40L, and sCD40L were
observed to be strongly up-regulated in course of active CD and
UC, particularly within the inflamed mucosa (30, 31, 33).
In patients with CD, CD40 is over-expressed on microvascular
endothelial cells in the inflamed mucosa, along with an increase
in CD40+ DCs found within the intestinal mucosa (38, 39). In
contrast, genomic association studies did not show a correlation
between the CD40 gene and IBD risk (40). Nonetheless, treatment
of CD patients with the antagonist chimeric monoclonal anti-
human CD40 antibody (ch5D12) showed a beneficial response
and remission rates of 72 and 22%, respectively (41).
Several studies have shown that animal models of rheumatoid
arthritis, experimental autoimmune encephalitis, and
lupus nephritis yielded first remarks for the importance of
CD40/CD40L pathways in immune diseases (42–44).
TheCD40/CD40L axis was a source of curiosity inmousemod-
els of IBD with a panoply of common pathogenic assets. Indeed, a
study conducted in vivo showed the relevance of the CD40/CD40L
system in the trinitrobenzene sulfonic acid (TNBS)-induced coli-
tis (36).
Antibodies against CD40L have been effective in preventing the
onset of the Th-1-driven colonic inflammation. This was due to
an inhibited IL-12 production by antigen-presenting cells and the
downstream lack of Th1 T cell priming. CD40L transgenic mice
with high transgene copy numbers were predisposed to develop
a lethal inflammation of the bowel. Moreover, mice showed a
severe colitis with histopathological features of IBD. The dis-
eased colon was marked by dense infiltrates of CD40L+CD4+
and CD8+ T cells and high numbers of CD40+ APCs (37).
Thus, the data available from animal models strongly suggest that
FIGURE 2 | CD40/CD40L in IBD. CD40/CD40L axis contributes to the activation of various pathways related to inflammation in immune and non-immune cells,
hence promoting IBD. In the early stages of mucosal inflammation, local T cells become activated and express CD40L, binding to and activating CD40+ DC.
Therefore, CD40+ DC enhances cytokine secretion, such as IL-12, and up-regulation of co-stimulatory activity including CD40, CD40L, and MHC-II activity
promoting more T cells that transmigrate into the interstitial space become activated with expressed CD40L. Activated T cells in the circulation of patients with IBD
contribute to this process through expression of CD40L on their surface.
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the CD40/CD40L system is a critical factor in the induction of
inflammatory cascade in IBD and could then represent a target
of treatment strategies.
Furthermore, similar tomultiple sclerosis and psoriasis, several
genetic associations and disease-causing alleles have been identi-
fied for IBD (4, 40). Although none of the genomic loci associated
with IBD incidence contain the CD40 gene (40), polymorphisms
in genes related to the Th17 pathway including IL-12B, STAT3,
and IL-23R confer increased risk of developing the disease (4, 40).
CD40 signaling in multiple cell types leads to the production of
IL-6, IL-12, and IL-23 and may, therefore, contribute to disease
initiation and/or progression in susceptible individuals (21). All in
all, Figure 2 summarizes all the events surrounding the potential
implication of the axis CD40/CD40L in IBD.
This review presents the contribution of the CD40/CD40L
axis in the pathogenesis of IBD. Better understanding of the
pathogenesis of this condition represents the background for the
progress in therapy. Data presented in this review are mainly
based on physiological and pathological mechanisms. However,
data from therapy approaches are highly relevant. Although the
introduction of various biological agents designed to neutralize
pro-inflammatory factors has been an important achievement
toward the control of IBD, no curative treatment is currently
available. In some animal models of colitis, anti-CD40L ther-
apy was demonstrated to be effective (35). Indeed, this study
demonstrated that administration of anti-CD40L to colitic mice
induced significant clinical and histological improvement and
down-regulated pro-inflammatory cytokine secretion. These data
suggest that the CD40–CD40L interactions are essential for
the Th1 inflammatory responses in the bowel in this exper-
imental model of colitis. Therefore, in view of their critical
role in the activation of antigen-presenting cells and T lym-
phocytes, targeting co-stimulating interactions of CD40/CD40L
in IBD is a potential approach of antibody therapy. Thus,
blockade of CD40 signaling may be beneficial to human IBD.
However, further studies should be done in order to shed
light on the importance of antibody therapy in the treatment
of IBD.
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